Details of the Drug

General Information of Drug (ID: DMX4938)

Drug Name

SDZ-LAP-977

Synonyms

SDZ-281-977

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Discontinued in Phase 2	[1]

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

316.3

Topological Polar Surface Area (xlogp)

4.1

Rotatable Bond Count (rotbonds)

7

Hydrogen Bond Donor Count (hbonddonor)

1

Hydrogen Bond Acceptor Count (hbondacc)

5

Chemical Identifiers

Formula: C18H20O5
IUPAC Name: methyl 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoate
Canonical SMILES: COC1=CC(=C(C=C1)OC)CCC2=CC(=C(C=C2)O)C(=O)OC
InChI: InChI=1S/C18H20O5/c1-21-14-7-9-17(22-2)13(11-14)6-4-12-5-8-16(19)15(10-12)18(20)23-3/h5,7-11,19H,4,6H2,1-3H3
InChIKey: GZOFTOHENYHNMS-UHFFFAOYSA-N

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004738)
2	Structure-activity relationship studies on a novel class of antiproliferative agents derived from Lavendustin A. Part I: Ring A modifications. Bioorg Med Chem. 2008 Aug 15;16(16):7552-60.
3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.